Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT06581198

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Led by Novartis Pharmaceuticals · Updated on 2026-02-20

179

Participants Needed

93

Research Sites

387 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

CONDITIONS

Official Title

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 18 to 75 years with systemic lupus erythematosus (SLE) meeting 2019 EULAR/ACR criteria
  • Positive for at least one lupus autoantibody: ANA (titer ≥1:80), anti-dsDNA, or anti-Sm
  • Active lupus nephritis without significant chronic damage or active SLE
  • SLEDAI-2K score of 6 or higher at screening, excluding fever, lupus headache, alopecia, or organic brain syndrome
  • Inadequate response to at least two prior therapies
Not Eligible

You will not qualify if you...

  • Acute, severe lupus flare needing immediate treatment other than pulse glucocorticoids or making immunosuppressive washout impossible
  • Inadequate organ function at screening
  • History or current ECG or cardiac abnormalities posing safety risks
  • Positive for HIV at screening
  • Acute or chronic hepatitis B or hepatitis C infection at screening
  • Grade 2 or higher thromboembolic event within 4 weeks before screening
  • Other protocol-defined exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 93 locations

1

University Of Alabama

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

Loma Linda University

San Bernardino, California, United States, 92408

Actively Recruiting

3

UCSF

San Francisco, California, United States, 94115

Actively Recruiting

4

UCSF

San Francisco, California, United States, 94115

Actively Recruiting

5

Sutter Health Network

San Pablo, California, United States, 94806

Actively Recruiting

6

Ann and Robert H Lurie Childs Hosp

Chicago, Illinois, United States, 60611

Actively Recruiting

7

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

8

University Of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

9

University of Kentucky

Lexington, Kentucky, United States, 40536-0284

Actively Recruiting

10

Tufts Medical Center

Boston, Massachusetts, United States, 02111

Actively Recruiting

11

Boston Medical Center

Boston, Massachusetts, United States, 02118

Actively Recruiting

12

WA Uni School Of Med

St Louis, Missouri, United States, 63110

Actively Recruiting

13

Oregon Health Sciences University

Portland, Oregon, United States, 97239

Actively Recruiting

14

Univ Of TX MD Anderson CC

Houston, Texas, United States, 77030

Actively Recruiting

15

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

16

LDS Hospital

Salt Lake City, Utah, United States, 84143

Actively Recruiting

17

LDS Hospital

Salt Lake City, Utah, United States, 84143

Actively Recruiting

18

Novartis Investigative Site

Clayton, Victoria, Australia, 3168

Actively Recruiting

19

Novartis Investigative Site

Graz, Austria, 8036

Actively Recruiting

20

Novartis Investigative Site

Vienna, Austria, 1090

Actively Recruiting

21

Novartis Investigative Site

Salvador, Estado de Bahia, Brazil, 41253-190

Actively Recruiting

22

Novartis Investigative Site

Barretos, São Paulo, Brazil, 14784 400

Actively Recruiting

23

Novartis Investigative Site

São Paulo, São Paulo, Brazil, 01232-010

Actively Recruiting

24

Novartis Investigative Site

São Paulo, São Paulo, Brazil, 01308-050

Actively Recruiting

25

Novartis Investigative Site

São Paulo, Brazil, 01509-010

Actively Recruiting

26

Novartis Investigative Site

Olomouc, Czechia, 779 00

Actively Recruiting

27

Novartis Investigative Site

Prague, Czechia, 128 00

Actively Recruiting

28

Novartis Investigative Site

Prague, Czechia, 128 08

Actively Recruiting

29

Novartis Investigative Site

Aarhus N, Denmark, 8200

Actively Recruiting

30

Novartis Investigative Site

Bordeaux, France, 33076

Actively Recruiting

31

Novartis Investigative Site

Marseille, France, 13005

Actively Recruiting

32

Novartis Investigative Site

Nantes, France, 44093

Actively Recruiting

33

Novartis Investigative Site

Paris, France, 75013

Actively Recruiting

34

Novartis Investigative Site

Paris, France, 75014

Actively Recruiting

35

Novartis Investigative Site

Strasbourg, France, 67091

Actively Recruiting

36

Novartis Investigative Site

Toulouse, France, 31054

Actively Recruiting

37

Novartis Investigative Site

Vandœuvre-lès-Nancy, France, 54511

Actively Recruiting

38

Novartis Investigative Site

Stuttgart, Baden-Wurttemberg, Germany, 70376

Actively Recruiting

39

Novartis Investigative Site

Frankfurt am Main, Hesse, Germany, 60528

Actively Recruiting

40

Novartis Investigative Site

Cologne, North Rhine-Westphalia, Germany, 50937

Actively Recruiting

41

Novartis Investigative Site

Leipzig, Saxony, Germany, 04103

Actively Recruiting

42

Novartis Investigative Site

Jena, Thuringia, Germany, 07740

Actively Recruiting

43

Novartis Investigative Site

Essen, Germany, 45147

Actively Recruiting

44

Novartis Investigative Site

Mainz, Germany, 55131

Actively Recruiting

45

Novartis Investigative Site

Nuremberg, Germany, 90419

Actively Recruiting

46

Novartis Investigative Site

Ulm, Germany, 89081

Actively Recruiting

47

Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, Hungary, 4032

Actively Recruiting

48

Novartis Investigative Site

Budapest, Hungary, H-1083

Actively Recruiting

49

Novartis Investigative Site

Ramat Gan, Israel, 5265601

Actively Recruiting

50

Novartis Investigative Site

Alessandria, AL, Italy, 15121

Actively Recruiting

51

Novartis Investigative Site

Ancona, AN, Italy, 60126

Actively Recruiting

52

Novartis Investigative Site

Genova, GE, Italy, 16132

Actively Recruiting

53

Novartis Investigative Site

Milan, MI, Italy, 20122

Actively Recruiting

54

Novartis Investigative Site

Milan, MI, Italy, 20132

Actively Recruiting

55

Novartis Investigative Site

Rozzano, MI, Italy, 20089

Actively Recruiting

56

Novartis Investigative Site

Pescara, PE, Italy, 65124

Actively Recruiting

57

Novartis Investigative Site

Pisa, PI, Italy, 56126

Actively Recruiting

58

Novartis Investigative Site

Pavia, PV, Italy, 27100

Actively Recruiting

59

Novartis Investigative Site

Sapporo, Hokkaido, Japan, 0608648

Actively Recruiting

60

Novartis Investigative Site

Kobe, Hyōgo, Japan, 6500047

Actively Recruiting

61

Novartis Investigative Site

Kanazawa, Ishikawa-ken, Japan, 920 8641

Actively Recruiting

62

Novartis Investigative Site

Yokohama, Kanagawa-ku, Japan, 236-0004

Actively Recruiting

63

Novartis Investigative Site

Sendai, Miyagi, Japan, 9808574

Actively Recruiting

64

Novartis Investigative Site

Suita, Osaka, Japan, 5650871

Actively Recruiting

65

Novartis Investigative Site

Izumo, Shimane, Japan, 693 8501

Actively Recruiting

66

Novartis Investigative Site

Bunkyo Ku, Tokyo, Japan, 1138431

Actively Recruiting

67

Novartis Investigative Site

Bunkyo-ku, Tokyo, Japan, 1138519

Actively Recruiting

68

Novartis Investigative Site

Chiba, Japan, 260 8677

Actively Recruiting

69

Novartis Investigative Site

Fukuoka, Japan, 8128582

Actively Recruiting

70

Novartis Investigative Site

Kyoto, Japan, 6068507

Actively Recruiting

71

Novartis Investigative Site

Leiden, South Holland, Netherlands, 2333 ZA

Actively Recruiting

72

Novartis Investigative Site

Groningen, Netherlands, 9713 GZ

Actively Recruiting

73

Novartis Investigative Site

Utrecht, Netherlands, 3584 CX

Actively Recruiting

74

Novartis Investigative Site

Oslo, Norway, 0372

Actively Recruiting

75

Novartis Investigative Site

Bucharest, Romania, 022328

Actively Recruiting

76

Novartis Investigative Site

Riyadh, Saudi Arabia, 11211

Actively Recruiting

77

Novartis Investigative Site

Singapore, Singapore, 119074

Actively Recruiting

78

Novartis Investigative Site

Seoul, South Korea, 06591

Actively Recruiting

79

Novartis Investigative Site

Santiago Compostela, A Coruna, Spain, 15706

Actively Recruiting

80

Novartis Investigative Site

Santander, Cantabria, Spain, 39008

Actively Recruiting

81

Novartis Investigative Site

Pamplona, Navarre, Spain, 31008

Actively Recruiting

82

Novartis Investigative Site

Barcelona, Spain, 08035

Actively Recruiting

83

Novartis Investigative Site

Córdoba, Spain, 14004

Actively Recruiting

84

Novartis Investigative Site

Madrid, Spain, 28009

Actively Recruiting

85

Novartis Investigative Site

Madrid, Spain, 28041

Actively Recruiting

86

Novartis Investigative Site

Salamanca, Spain, 37007

Actively Recruiting

87

Novartis Investigative Site

Valencia, Spain, 46026

Actively Recruiting

88

Novartis Investigative Site

Stockholm, Sweden, 17176

Actively Recruiting

89

Novartis Investigative Site

Lausanne, Switzerland, 1011

Actively Recruiting

90

Novartis Investigative Site

Taichung, Taiwan, 407219

Actively Recruiting

91

Novartis Investigative Site

Taipei, Taiwan, 10002

Actively Recruiting

92

Novartis Investigative Site

Sheffield, South Yorkshire, United Kingdom, S10 2JF

Actively Recruiting

93

Novartis Investigative Site

London, United Kingdom, W12 0HS

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | DecenTrialz